By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Octapharma AG 

Seidenstraße 2

Lachen    CH-8853  Switzerland
Phone: 41-55-451-2121 Fax: 41-55-451-2110



Company News
Octapharma AG Presents Key Data With Nuwiq In Previously Untreated Patients From The Nuprotect Study At American Society of Hematology (ASH) Annual Meeting In San Diego, USA 12/21/2016 11:45:50 AM
Octapharma AG To Sponsor Two Symposia At The 2016 World Federation Of Hemophilia (WFH) World Congress In Orlando, USA 7/22/2016 7:51:30 AM
Zika Virus Guidance From FDA Notes Safety Of Plasma Protein Products And The Availability Of Octapharma AG’s Octaplas 3/7/2016 10:29:16 AM
Octapharma AG Selects IDBS' E-WorkBook 10 2/9/2016 8:16:52 AM
Octapharma AG Invests €80 Million to Acquire an Exclusive Worldwide License to Certain IP of Glycotope’s Technology 10/8/2015 5:58:45 AM
Octapharma AG Announces Octagam® 10% Now Available For Ordering In U.S. 10/27/2014 10:55:41 AM
European Commission (EC) Publishes Approval Of Octapharma AG’s Human Cell Line Recombinant FVIII (Nuwiq®) Across All Age Groups In Haemophilia A 8/6/2014 10:12:06 AM
Octapharma AG Sponsors Symposium “Spotlight On The Human Factor: Building A Foundation For The Future Of Haemophilia A Management" At 2014 WFH World Congress In Melbourne, Australia 5/27/2014 7:08:02 AM
Octapharma AG Phase 2/3 Trial For The Targeted Treatment Of Relapsing Multiple Sclerosis Enrols First Patients 12/18/2013 9:32:30 AM
Octapharma AG Enters Into Agreement With Pfizer Inc. (PFE) For The Future Commercialization And Marketing In The U.S. Of An Investigational Intravenous Therapy For The Urgent Reversal Of An Oral Anticoagulant 12/11/2013 9:48:06 AM